The Lambda Variant (C.37) of SARS-CoV2 Has Higher Infectivity and Immune Escape

The Lambda variant (lineage C.37) of SARS-CoV-2 was identified in Southern Brazil. This was found to have high prevalence in some south America. In view of high rates of transmissibility across south America, this variant was declared to be a variant of interest or variant under investigation (VOI) by WHO on June 15, 2021.1,2  

The Lambda variant has critical mutations in spike proteins. The impact of the mutations on infectivity and immune escape from neutralising antibodies were unknown. A recent study indicates that the mutations in the spike protein of Lambda variant increases infectivity and immune escape from neutralizing antibodies.This information makes genomic studies of the mutants and immunological studies an imperative including studying if the existing vaccines are effective against the variants.  

In view of this finding, it is normal to wonder if the current vaccines against COVID-19 will remain effective against the new variants like the Lambda which has critical mutations in the spike protein. It is argued that the existing vaccines should provide at least some protection against the new variants because the vaccines trigger a broad immune response in which range of cells and antibodies are involved. Hence, vaccines would not become completely ineffective because of mutations in the spike protein. Further, there is always the possibility of fine-tuning the antigenic nature of the vaccines to cover the mutations for protection against the variants.

***

References:  

  1. Wink PL, Volpato FCZ, et al 2021. First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. Posted June 23, 2021. doi: https://doi.org/10.1101/2021.06.21.21259241    
  1. Romero PE, Dávila-Barclay A, et al 2021.The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America. Posted July 03, 2021. doi: https://doi.org/10.1101/2021.06.26.21259487  
  1. Acevedo ML, Alonso-Palomares L, et al 2021.Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. Posted July 01, 2021. doi: https://doi.org/10.1101/2021.06.28.21259673  
  1. WHO, 2021. The effects of virus variants on COVID-19 vaccines. Available online at https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines?gclid=EAIaIQobChMIyvqw5_zQ8QIVCLqWCh2SkQeYEAAYASAAEgLv__D_BwE Accessed on 07 July 2021.  

***

Don't miss

Interferon-β for Treatment of COVID-19: Subcutaneous Administration more Effective

Results from the phase2 trial support the view that...

COVID‑19: National Lockdown in the UK

To protect the NHS and save lives., National Lockdown...

A Novel Approach to ‘Repurpose’ Existing Drugs For COVID-19

A combination of biological and computational approach to study...

Did the SARS CoV-2 Virus Originate in Laboratory?

There is no clarity on the natural origin of...

‘Bradykinin Hypothesis’ Explains the Exaggerated Inflammatory Response in COVID-19

A novel mechanism to explain the different unrelated symptoms...

Stay in touch:

92,144FansLike
45,781FollowersFollow
1,772FollowersFollow
51SubscribersSubscribe

Newsletter

Latest

COVID-19 in 2025  

The unprecedented COVID-19 pandemic spanning over three years claimed...

CoViNet: A New Network of Global Laboratories for Coronaviruses 

A new global network of laboratories for coronaviruses, CoViNet,...

COVID-19: Severe lung infection affects heart through “cardiac macrophage shift” 

It is known that COVID-19 increases the risk of...

JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25...

COVID-19: JN.1 sub-variant has higher transmissibility and immune escape ability 

Spike mutation (S: L455S) is hallmark mutation of JN.1...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

WHO’s Interim recommendations for the use of One-dose Janssen Ad26.COV2.S (COVID-19) vaccine

Single dose of the vaccine can increase vaccine coverage rapidly which is an imperative in many countries where level of vaccine uptake is not optimal.   WHO...

Omicron BA.2 Subvariant is More Transmissible

Omicron BA.2 subvariant seems to be more transmissible than BA.1. It also possesses immune-evasive properties that further reduce the protective effect of vaccination against...

How Omicron Variant of COVID-19 may have Arisen?

One of unusual and most intriguing feature of heavily mutated Omicron variant is that it acquired all the mutations in a single burst in a...